Posted by Michael Wonder on 28 Mar 2020
Bristol Myers Squibb receives positive CHMP opinion recommending approval of Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease
28 March 2020 - Bristol Myers Squibb today announced that the CHMP of the European Medicines Agency has adopted a positive opinion for Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
ZEPOSIA is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).
The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.
